REFERENCES:

1. Abma et al., (2010). Teenagers in the United States: sexual activity, contraceptive use, and childbearing, national survey of family growth. Vital Health Statistics 23, 30 (6):1-47.
2. Birth Control Methods, U. S. Department of Health and human services, Office on Women's health; 1-13.
3. Black et al., (2004). Canada contraception consensus, SOGC clinical practice guideline, 143; 1-36. Combined oral contraceptive
4. Burkman et al.(2002). The Transdermal contraceptive patch: a new approach to hormonal contraception. International Journal of Fertilization. 47: 69-76.
5. Croxatto et al.(2000). A clinical profile of Implanon: a single rod Etonogestrel contraceptive implant. European journal of contraceptive reproduction health care. 5(Suppl.2): 21-28.
6. Diczfalusy et al., (1996). Probable mode of action of oral contraceptives. Res Steroids; 2:389–92.
7. Gaffield et al (2006). Medical eligibility criteria for new contraceptive methods combined hormonal patch, combined hormonal vaginal ring and the Etonogestrel implant, contraception 73, 134 – 144.
8. Gbolade et al., (1998). Bone density in long term users of depot medroxyprogesterone acetate, British journal of obstetrician and gyenocology.105;790-4
9. Iyer et al., (2003). Oral contraceptive pills for heavy menstrual bleeding: the Cochrane database of systematic reviews: 4.
10. Kaunitz et al., (1994). Long acting injectable contraception with depot medroxyprogesterone acetate, Journal of Obstretion and Gynaecology, 170; 1543.

11. Kerscher et al., (2007). Chlormadinonacetat enthaltene Mikropille verbessert unreine Haut. Ergebnisse der CEFIS (Chlormadinonacetat Ethinylestradiol for Impure Skin)-Studie. Frauenarzt; 48: 373–78.
12. Mahmood et al., (1998). The effect of ovarian steroids on epithelial ciliary beat frequency in the human fallopian tube, Human Reprod, 3; 2991–4.
13. Milson et al., (1992). The influence of a low dose combined oral contraceptive on menstrual blood loss and iron status, contraception; 46(4), 327-34.
14. Mishell et al., (1977). The effect of contraceptive steroid on hypothalamic-pituitary function. Journal of Obstretion Gynaecology, 128; 60-74.
15. Mitra et al., (1987). Effect of oral contraceptives on the ultra structure of the endometrium. J Gynecol Endocrinal.; 3(1-4):13–5.
16. Oral contraceptive methods (2012). DHMH/FHA/CMCH Maryland Family Planning & Reproductive Health Program Clinical Guidelines; 1-15.
17. Rossmanith et al., (1997). A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity. Contraception; 56 (1): 23–30.
18. Roumen et al., (1996). The cervico vaginal epithelium during 20 cycles' use of combined contraceptive vaginal ring, Human Reproduction, 11; 2443-8.
19. Savasi et al., (2009). Menstrual suppression for adolescent with developmental disabilities, Journal of Pediatric and Adolescent Gynaecology, 22; 143-149.
20. Schramm et al., (2000). Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara®), Clinical. Drug Investigation. 22: 221–31.
21. Schramm et al., (2003). A 12-month evaluation of the CMA containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties, Contraception; 67: 305–12.
22. Schramm et al., (2007). Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception.76: 84–90.

23. Skobuy et al., (2004). Contraceptive use and behaviour in the 21st century: a comprehensive study across five European countries. European Journal of Contraception Reprod Health Care; 9: 57–68.

24. Society of Obstetricians and Gynecologists of Canada (2004). SOGC clinical practice guidelines: Canadian contraception consensus (No. 143).

25. Trussell et al., (2004). The essentials of contraception: efficacy, safety, and personal considerations. Contraceptive technology. New York: Ardent Media, Inc. p. 224–34.

26. Worret et al., (2001). Acne resolution rates: results of a single-blind, randomized, and controlled parallel phase III trial with EE/CMA and EE/LNG (Microgynon). Dermatology, 203: 38–44.

27. Wright et al., (2008). Evaluation of extended and continuous use oral contraceptive, therapeutic and clinical risk management:4(5) 905-911.

28. Wulf et al., (1999). Sharing Responsibility: women, society and abortion worldwide, New York 7 the Alan Guttmacher institute.

29. Zahradnik et al., (1998). Efficacy and safety of the new anti androgenic oral contraceptive Belara. Contraception; 57: 103–9.

30. Zahradnik et al., (2005). Belara a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoeal. European Journal of Contraception Reprod Health Care, 10 (Suppl 1):12–8.

31. Zieman et al., (2010-2012). Managing contraception for your pocket: Atlanta, GA: Bridging the Gap Communications; 1-9.

Dr. Anil Middha. **Narottam Rangrao Shinde.**

(Guide) **(Ph.D Research Scholar)**